INDSWFTLTDNSEInd-Swift Limited· PharmaceuticalsMediumNegative
Announced Mon, 14 Jul · 17:56 IST

The Exchange had sought clarification from Ind-Swift Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.

Regulatory & Legal View source PDF
Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

NSE sought clarification from Ind-Swift Limited because the standalone and consolidated financial results submitted for the quarter and year ended March 31, 2025 showed identical figures and were not in the SEBI-prescribed format. The company explained that its wholly owned subsidiary, Ind-Swift India Limited (set up in Kenya in May 2022), has not yet started commercial operations, so its financials were NIL for the year. This caused the standalone and consolidated numbers to be the same. The company stated there has been no deviation in reporting and the disclosure complies with applicable regulations.

Likely market impact

This is a routine format-level clarification and not a regulatory action. Shareholders should note that the subsidiary remains non-operational, which explains the duplicate figures. No financial or governance concern is indicated beyond the formatting issue raised by the exchange.